Achillion Pharmaceuticals, Inc. (ACHN) Misses Q4 EPS by 2c; Guides FY12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts ACHN Hot Sheet
Join SI Premium – FREE
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) reported Q4 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $62 thousand versus the consensus estimate of $120 thousand.
Sees FY2012 EPS of $-0.65-$-0.70, versus the consensus of $-0.64.
For earnings history and earnings-related data on Achillion Pharmaceuticals, Inc. (ACHN) click here.
Sees FY2012 EPS of $-0.65-$-0.70, versus the consensus of $-0.64.
For earnings history and earnings-related data on Achillion Pharmaceuticals, Inc. (ACHN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Viasat stock rises on Raymond James target reiteration
- Standard Motor Products CFO to resign, interim replacement named
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
